NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Priority Review
NEPHROSCAN (succimer) by Evergreen Therapeutics is lead chelating activity [moa]. Approved for lead poisoning in pediatric patients aged 1 year, older with blood lead levels above 45 mcg/dl, lead poisoning in a lead-containing environment and 1 more indications. First approved in 2022.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEPHROSCAN (succimer) is an intravenous lead chelator approved in February 2022 for treating lead poisoning in pediatric patients aged 1 year and older with blood lead levels above 45 mcg/dL. It works by binding lead ions and facilitating their urinary excretion, preventing neurotoxic complications including lead encephalopathy. The drug addresses a critical public health need in lead-exposed populations.
Peak
Peak-stage product with early-cycle momentum; commercial teams remain lean with growth potential as awareness expands in pediatric and public health settings.
Mechanism of Action
Lead Chelating Activity
Pharmacologic Class:
Lead Chelator
Worked on NEPHROSCAN at Evergreen Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.